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ABSTRACT
Objectives: To assess whether delaying risk reduction
treatment has a different impact on potential life years
lost in younger compared with older patients at the
same baseline short-term cardiovascular risk.
Design: Modelling based on population data.
Methods: Potential years of life lost from a 5-year
treatment delay were estimated for patients of different
ages but with the same cardiovascular risk (either 5%
or 10% 5-year risk). Two models were used: an age-
based residual life expectancy model and a Markov
simulation model. Age-speciﬁc case fatality rates and
time preferences were applied to both models, and
competing mortality risks were incorporated into the
Markov model.
Results: Younger patients had more potential life
years to lose if untreated, but the maximum difference
between 35 and 85 years was <1 year, when models
were unadjusted for time preferences or competing
risk. When these adjusters were included, the
maximum difference fell to about 1 month, although
the direction was reversed with older people having
more to lose.
Conclusions: Surprisingly, age at onset of treatment
has little impact on the likely beneﬁts of interventions
that reduce cardiovascular risk because of the
opposing effects of life expectancy, case fatality, time
preferences and competing risks. These ﬁndings
challenge the appropriateness of recommendations to
use lower risk-based treatment thresholds in younger
patients.
INTRODUCTION
A common criticism of using short-term (eg,
5- or 10-year) cardiovascular disease (CVD)
risk calculators is that they strongly favour
treating older individuals who generally have
high short-term risk but lower life expect-
ancy.
1e3 Intuitively, a young person at the
same short-term CVD risk as an old person
would appear to lose more in terms of life
years simply because of their longer life
expectancy. The dilemma is brought into
sharpest focus when we consider patients at
the same short-term risk but of different ages.
Given a predicted CVD risk, of say 20% in
10 years, who stands to gain more from
treatment: the young or the old patient?
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ARTICLE SUMMARY
Article focus
- Short-term cardiovascular risk scores have been
criticised as being biased towards treatment of
older patients and for leading to delayed
treatment in younger patients.
- The fundamental question remains as to whether
there is a true difference in potential life years
lost for patients of different ages but with the
same short-term cardiovascular risk.
- We used mathematical models to compare the
potential life years lost for a 5-year treatment
delay versus no delay obtained for patients at
different ages but at the same short-term
coronary heart disease (CHD) risk. These
models incorporate age-speciﬁc case fatality
rates, competing risks and time preference.
Key messages
- Patient age at onset of treatment will have little
impact on the likely beneﬁts of interventions that
reduce cardiovascular risk.
- This is because of the opposing effects of life
expectancy, case fatality, time preferences and
competing risks.
- These ﬁndings challenge the appropriateness of
recommendations to use lower risk-based treat-
ment thresholds in younger patients.
Strengths and limitations of this study
- Two different models were used and the results
corroborate. Neither relies on the use of
a particular risk score.
- The models only accounted for life years lost due
through death and not quality of life lost due to
non-fatal events. As the severity of non-fatal
events also increases with age, the direction of
the ﬁndings would likely be similar if these
events were included.
- Only case fatality rates for CHD were used in the
models as relevant data for total cardiovascular
disease were not available. The results are
unlikely to change with the addition of cerebro-
vascular disease as 5-year case fatality rates by
age are similar for CHD and stroke.
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Open Access ResearchThis apparent limitation of short-term CVD risk
prediction may explain the increasing interest in models
that attempt to redress the perceived imbalance towards
treating older people, such as lifetime CVD risk predic-
tion models.
3 4 These models are promoted as being
better at identifying individuals who do not reach the
recommended treatment threshold using standard 5- or
10-year risk calculators
5 but have an increased relative
risk (RR) of CVD compared with their peers: mainly
young men with multiple but modestly increased risk
factors.
3 It has been proposed that these individuals, who
are at low 10-year risk but high lifetime risk, should be
started on treatment.
Experts, however, have questioned the use of such
approaches in clinical practice.
6 7 It is true that older
people have a shorter life expectancy than the young but
they also have higher case fatality rates after a cardiovas-
cular event.
8 The case fatality rates from other
competing risks, that is, non-CVDs, are also higher with
increasing age. The consequences of using lifetime risk
assessment would mean that larger numbers of young
asymptomatic individuals would be expected to take
drugs every day for many years, potentially causing short-
term harm, in order to prevent or delay an event
occurring in the far-off future. Indeed, the lifetime risk
approach may not accurately represent the decisional
issues as it ignores three important factors: age-speciﬁc
case fatality rates, competing risks and ‘time preferences’
that value the near future over the distant future.
This study addresses the fundamental question: is
there a true difference in potential life years lost for
patients of different ages but with the same short-term
cardiovascular risk? If there is no difference, then
attempts to correct the perceived imbalance are unnec-
essary and will have unintended harmful consequences.
In this paper, mathematical models were used to quan-
tify the size and direction of any differences in losses of
young and old patients at identical short-term risks of
CVD. These models incorporate the factors of age-
speciﬁc case fatality rates, competing risks and time
preference.
METHODS
In order to answer the question of whether the young
and old should be treated differently, a comparison of
potential life years lost for a 5-year treatment delay versus
no delay is obtained for patients at different ages but at
the same short-term coronary heart disease (CHD) risk.
This simulates a scenario where two patientsdone young
and the other olddpresent with identical absolute CHD
risks; does one patient suffer greater potential life year
loss from a 5-year treatment delay than the other?
Figure 1 illustrates the method used to address the
study question. First, the life expectancy is calculated for
a person in the age group 35e39 at a speciﬁed 5-year
CHD risk (for example, 10%) who remains untreated
(top arrow). Next, the life expectancy of a person of
identical age and risk is estimated but with the CHD risk
for the ﬁrst 5 years reduced to zero (the hypothetical
treatment is assumed to be 100% effectivedsecond
arrow). The difference in life expectancy from the
results of both arms gives the potential years of life lost
(PYLL) due to a treatment delay of 5 years for that age
and CHD risk.
Figure 1 also shows how the same process is used to
determine the PYLL due to a treatment delay for
a person in the age group 50e54 at the same CHD risk
as the younger person. The PYLL
35e39 can then be
compared with the PYLL
50e54 to compare the life years
lost with treatment delay at different ages but at the same
absolute risk level.
The process was repeated for different age groups
from age 35 to 85. This allows the graphical comparison
and detection of trends of losses due to treatment delay
at different ages but at the same speciﬁed absolute risk
level.
Treatment is assumed to be 100% effective. While this
will exaggerate the absolute effect of treatment, it
provides a valid relative comparison of the PYLL for
a treatment delay of 5 years at different ages and at
different risk levels. The difference of 100% effectiveness
applies to all strategies, so it ‘overestimates’ equally for
all; it would give the same relative results if a 30% or 50%
reduction was used.
Two different modelling approaches (age-based
residual life expectancy models and Markov simulation
cohort models) are used to determine the PYLL by not
initiating treatment earlier in patients with the same 5-
year CHD risk but at different ages. Five-year risk levels
of 5% and 10% were selected, as they are approximately
equivalent to 10-year risks of 10% and 20%dthe key
thresholds in UK and European guidelines.
9 10
Sensitivity analysis was conducted by the use of two
different models and various time preference rates.
Age-based residual life expectancy model
In this model, the hypothetical treated cohort has a zero
risk of CHD death during the 5-year treatment period,
Figure 1 Method used to estimate the potential years of life
lost for a 5-year treatment delay in older and younger patients
with the same 5-year cardiovascular disease risk. Arrows
indicate life expectancies in those treated from baseline for
5 years (red part of lower arrow for each patient) and those not
treated.
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5 years and then uses the average further life expectancy
(beyond the 5 years) for the population to calculate the
PYLL. The calculation was done with and without a time
preference rate to account for the increasingly lower
value that patients currently give to life years further out
into the future. The preference rate accounts for both
the uncertainty surrounding future events (‘risk aver-
sion’) and the natural preference for present gratiﬁca-
tion as compared with future beneﬁt (time preference).
A positive time preference rate is placed on later years,
meaning that the further it is in the future, the smaller
the value of that life year.
11 12
The formula for life expectancy with time preference
is
13
Life expectancy with time preferencer ¼
1
r
$
"
1 
1
ð1þrÞ
LE
#
;
where r is the time preference rate and LE is the national
life expectancy estimates. A minimal time preference
rate of 0.03 was used, which values the next year as worth
97% of the previous year. This preference rate is applied
throughout the remaining estimated years of life of the
cohort.
The PYLL due to being exposed to a set CHD risk level
at different ages was then calculated using the following
formula:
Potential life years lost at age A¼ CHD risk3CFRA3LEr;
where CHD is coronary heart disease, CFR is the age-
speciﬁc case fatality rate and LEr is the life expectancy
with time preference. Estimated life expectancy by age
and sex was obtained from interim life tables for the
years 2005e2007 from the Ofﬁce of National Statistics,
UK.
14 Case fatality rates by age and sex for 1994e1998
were obtained from a 2001 report to the UK Department
of Health on data from the Oxford record linkage
study.
15
Markov simulation cohort
As with the ﬁrst (age-based residual life expectancy)
model, the hypothetical treated cohort in the Markov
model has a zero CHD mortality risk during the 5-year
treatment period. However, in contrast to the ﬁrst
model, the Markov model subsequently differentiates
between the ongoing competing risks of death, CHD
and non-CHD, of both the treated and untreated hypo-
thetical cohorts.
The Markov model calculates the life expectancy of
simulated cohorts with 100 hypothetical people for 5-
year age groups starting from 35 (ie, 35e39, 40e44, etc).
The cohorts were modelled with a base CHD risk of 5%
in 5 years, and the process was repeated using a base
CHD risk of 10% in 5 years. All the cohort members start
in the ‘well state’. The length of each cycle is set at
5 years. In every cycle, we calculate the numbers who die
due to CHD (starting with the base CHD risk speciﬁed
and age-speciﬁc myocardial infarction (MI) case fatality
rates
15) and those due to non-CHD using non-CHD case
fatality rates.
16 17 Non-CHD rates were derived from the
Ofﬁce of National Statistics on UK death registrations by
age, sex and underlying cause and population estimates
for 2007.
16 17 We used the RR of CHD per year of
increasing age (RR¼1.05 for men and RR¼1.04 for
women) as given by the Framingham study
18 to calculate
the increase in CHD risk in each cycle. The process is
repeated, moving more and more members into the
‘dead state’, until the cycle sum falls below 1 person-cycle
where every member is dead.
19 The life expectancy of
the cohort is obtained by adding up the number of
person life years in the ‘well’ column. For the same age
band, we repeat the process using the same rates except
that for the ﬁrst cycle, the CHD risk is reduced to 0. The
potential life years lost for one person is then calculated
by the following formula:
PYLL at age A ¼
 
LE
COHORT WITH BASE RISK
 LE
COHORT INITIAL RISK 0  
10035:
This, in effect, allows the results of the simulation to be
comparable to the ﬁrst method.
We then applied a time preference rate with half cycle
correction to the Markov simulation cohort model. The
Markov simulation cohort assumes that transition from
one state to another occurs between cycles and that the
number of participants in each state remains stable
during the cycle. If membership of the cohort is counted
at the beginning of the cycle, this leads to overestimation
of the life expectancy of the cohort. If counted at the
end of the cycle, there is underestimation of the life
expectancy of the cohort. To correct this, a half cycle
correction is employed whereby transition is assumed to
occur halfway through the cycle.
19
RESULTS
Using a time preference rate of 0.03, the life expectan-
cies for different age groups were obtained as shown in
table 1. Figure 2 shows the PYLL with and without using
the time preference rate of 0.03.
Figures 2 and 3 show the results obtained from both
models. The black lines represent the age-based residual
life expectancy models and the red lines represent the
Markov models. The dotted lines indicate the results of
the models without time preference and the solid lines
for those with time preference.
The PYLL from delaying treatment by 5 years for
different ages for both the 5% and 10% 5-year CHD risk
levels can be read from the graphs. For example, the
results show that for a treatment delay of 5 years, the
PYLL over a lifetime for a 35e39-year-old person at 10%
5-year CHD risk is slightly >1 year in the age-based
residual life expectancy model and 0.75 year in the
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Should identical CVD risks in young and old patients be managed identically?Markov model when time preference is not taken into
account.
As expected, the PYLL is higher for all models at 10%
risk compared with that for 5% risk.
The estimated PYLL in the age-based residual life
expectancy model without time preference for the
cohorts with both 5% and 10% 5-year CHD risk has
a downward slope with increasing age, indicating that
younger age groups have more potential life years to lose
than older age groups at the same CHD risk level.
Although this appears quite steep, the actual difference
is only a maximum of about 0.70 years (8.5 months) in
the 10% risk model. Moreover, in the Markov model,
which accounts for competing causes of death in addi-
tion to the age-speciﬁc case fatality rates, the maximum
difference in PYLL between the youngest and oldest age
categories reduces to about 0.20 years (2.5 months).
With the application of a minimal (3%) time prefer-
ence rate, the difference in PYLL almost disappears for
the age-based residual life expectancy model in the age
range from 35e39 to about 70e74 years. In the older age
groups (over about 75 years), the time preference
adjustment has a minimal effect.
When time preference is incorporated into the Markov
model, there is some indication of an upward trend in
PYLL with increasing age from the age groups 35e39 to
Table 1 Estimates of life expectancy, UK; without time preference (r¼0) and with a time preference rate (r¼0.03)
Age group
Age-speciﬁc CHD
case fatality rates (%)
5-year CHD death
rate (%) for 5%; 10%
5-year CHD risk
Life expectancy (yrs)d
national estimates without
a time preference
Life expectancy with
time preference rate
of 0.03
35e39 25.9 1.3; 2.6 41.65 23.6
40e44 29.1 1.5; 2.9 36.95 22.15
45e49 30.7 1.5; 3.1 32.33 20.51
50e54 33.1 1.7; 3.3 27.85 18.7
55e59 33.6 1.7; 3.4 23.55 16.72
60e64 42.3 2.1; 4.2 19.46 14.58
65e69 51.8 2.6; 5.2 15.69 12.37
70e74 56.5 2.8; 5.7 12.24 10.12
75e79 64.5 3.2; 6.5 9.23 7.96
80e84 70.3 3.5; 7.0 6.77 6.05
85+ 79.2 4.0; 7.9 4.87 4.47
CHD, coronary heart disease.
Figure 2 Potential years of life lost (PYLL) for men at 5-year 5% coronary heart disease riskdwith and without time preference.
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with age, time preference and competing risks are
considered, there is no difference in PYLL from delaying
treatment for 5 years, for men at different ages with the
same CHD risk.
The analysis was sensitive to the time preference rate
used, though for typical rates the PYLL was similar at
different ages. The sensitivity analysis also showed that
an increase in time preference rate would actually
increase the PYLL at older age groups.
DISCUSSION
Statement of principal ﬁndings
Clinicians are increasingly being advised to use short-
term CVD risk prediction tools to help determine the
effects of multiple risk factors on their patients’ risks of
developing CVD and to help weigh the beneﬁts and costs
of starting treatment in individual patients. Intuitively,
short-term risk prediction does not appear to acknowl-
edge that younger people have a longer life expectancy
and would lose more years of life following a CVD event
than older people who have a shorter life expectancy.
However, our ﬁndings suggest that the additional beneﬁt
to life expectancy by preventive therapy in younger
compared with older patients is counterbalanced by
a number of opposing factors.
First, younger patients have lower case fatality rates.
That is, in younger individuals with the same short-term
CVD risk as older individuals, fewer will die from the
eventandonlythosefewwhododiewillloseanylifeyears.
Second, older individuals also face increasing risks of
other causes of death that ‘compete’ with their CVD risk.
In other words, for a given estimated 5-year CVD
mortality risk, older people are more likely to die of
another cause than younger people. This effect is illus-
trated by the difference between the results of the age-
based residual life expectancy model, which does not
account for competing risk, and the Markov simulation
cohort method, which does.
Finally, each of the ‘potential life years lost’ is not
considered as equal by patients. A life year in the far-
off future is unlikely to be valued as much as one in
a near future, especially when there exist the possibility
of harm and other immediate costs due to the inter-
vention. Balanced treatment decisions should therefore
account for how people value future events. We have
done this by modelling a time preference rate. We used
a time preference rate of only 3% and even this
minimal rate had a major effect on the potential life
years lost; for the same cardiovascular risk, there is
little difference in potential life years lost at different
ages.
These ﬁndings suggest that models that do not take
the factors of case fatality rates, time preference and
competing risks into account will overestimate the
beneﬁts of treatment in younger patients and may
possibly underestimate the beneﬁts in older people.
Strengths and weaknesses of the study
This study suggests that there is little difference in the
potential life years lost by delaying treatment in younger
compared with older patients who have the same esti-
mated short-term cardiovascular risk. Two different
methods were used and the results corroborate. Neither
Figure 3 Potential years of life lost (PYLL) for men at 5-year 10% coronary heart disease riskdwith and without time preference.
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Should identical CVD risks in young and old patients be managed identically?method relies on the use of a particular risk score,
meaning that the ﬁndings are applicable across a wide
range of risk.
A potential limitation of this study is that both
methods only took into account life years lost through
death and not quality of life lost as a result of non-fatal
events. However, the severity of non-fatal events is also
likely to increase with age, so it is unlikely that including
non-fatal events in the models would change the direc-
tion of the ﬁndings. Moreover, there is no robust
evidence on the impact of CVD events on the quality of
life at different ages and therefore we considered it
unlikely that the added number of assumptions required
and increased complexity of analyses would generate
more meaningful conclusions.
The complexity of the models could have been
increased by including multiple disease states. For
example, a ‘post-CHD’ state could have been added to
the three states included (ie, ‘well’, ‘CHD death’ and
‘non-CHD death’) as those who survived an event would
have a higher than normal risk of CHD and death. Other
states were also options; for example, the model could
have incorporated states of post double or triple CHD
events, different types of events such as heart failure and
so on. However, all models are approximations and the
models used here allow a satisfactory differentiation
between the young and old with minimal bias. The
addition of other states would necessitate greater
assumptions, which would increase complexity but not
necessarily the accuracy as additional bias and uncer-
tainty is also increased.
Also, the models did not take account of case fatality
rates from cerebrovascular disease (only CHD case
fatality was used) as we were unable to ﬁnd case fatality
rates for total CVD for the UK population data used by
our models. However, a study in New Zealand
20 and
another from Sweden
21 showed that the 5-year case
fatality by age is similar for deﬁnite MI, other CHD and
stroke. Hence, the addition of cerebrovascular disease,
that is, stroke, is unlikely to cause a signiﬁcant change in
our results.
Strengths and weaknesses in relation to other studies,
discussing particularly any differences in results
The QRISK group in the UK has recently developed
a lifetime CVD risk calculator. Using a threshold of
>50% lifetime risk of CVD disease, over half of men
identiﬁed as being at high risk were in the youngest age
group (30e44 years of age). In women, over one-third
were in this age group.
3 The authors presented several
case studies that raised concerns about the clinical
usefulness of lifetime risk and stated that they were
uncertain whether using such an approach was appro-
priate for treatment decisions. Yet recent media articles
have suggested new national UK guidelines will change
from advocating the use of 10-year risk to lifetime risk
calculators in clinical practice.
7
In Norway, a different approach has been adopted
where thresholds for treatment are different for
different ages. For those aged 40e49 years, the threshold
is set at a 10-year risk of CVD death of 1%, whereas for
those aged 60e69 years, it is set at 10%. The new
recommendations are based on a Markov model, which
showed that more life years were gained using age-
differentiated thresholds. Their model adjusted for the
increase in case fatality rates with age but did not
account for time preference or competing risks.
22
This is a cause for concern given that our study
demonstrates that the adoption of approaches such as
these that seek to redress the issue of age in short-term
risk scores overestimate the CVD in younger people and
lead to a substantial (and unnecessary) increase in the
number of young people on medication.
Montgomery et al
23 used simulation models to estimate
the effectiveness and cost-effectiveness of blood pres-
sure-lowering treatment over a lifetime. One of their
objectives was to compare the increase in life expectancy
from treatment at different ages. This appears to be
similar to our objectivedthey measured gains from
treatment, while we examined losses from treatment
delay. However, their model evaluated lifetime treatment
versus lifetime non-treatment. Our models sought to
answer the impact of only a 5-year delay. This is a crucial
difference. The young person who presents at one point
in time with a cardiovascular risk score that is higher
than average for his age group will be monitored and
assessed again at a future point in time. This will mean
that he is likely to receive treatment as he ages. There-
fore, to compare treatment and no treatment for a
lifetime is not a clinically relevant comparison.
The ‘low-’ and ‘high-risk’ proﬁles used in the Mont-
gomery model are also based on age-speciﬁc mean
values for systolic blood pressure and centile values for
other risk factors. As the values used are age speciﬁc, it is
likely that the absolute risk category for the young and
old are different, that is, the low-risk elderly is likely to
have overlapping absolute risk with the high-risk young
in the model. The differentiation of absolute risk by this
method would be smaller in the older age groups and
bigger in the younger age groups resulting in a reduc-
tion of gains in life expectancy with treatment as age
increases. This would account for the greater gains in life
expectancy seen in the young compared with the old in
their paper.
Meaning of the study: possible mechanisms and
implications for clinicians or policymakers
Our ﬁndings show that there is minimal difference in
potential life years lost from delaying treatment for
5 years in younger and older patients when important
and objective factors such as case fatality rates and
competing risks are considered. When a time preference
adjuster is also added, the difference is largely abolished.
This suggests that the use of models that preferentially
treat younger over older patients would mean that
a number of low-risk individuals would be exposed to
long-term medication with questionable beneﬁts and an
even greater number of those in older age groups would
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develop preventable CVD.
Unanswered questions and future research
In examining the use of CVD risk for young versus old
patients, we have only addressed the issues of age-speciﬁc
case fatality rates, competing risks and time preference.
However, there are other factors that clinicians and
patients may consider when making treatment decisions
based on CVD risk. Both the frequency and impact of
adverse effects may differ between young and old. The
older people may also have a different attitude to
mortality and may consider the mode of death as well as
the timing of death. Further research is needed to
address the impact of these issues on the use of CVD risk
in cardiovascular risk management.
CONCLUSIONS
When case fatality rates, competing risks and time pref-
erence are taken into account, there appears to be
minimal differences in the potential life years lost from
experiencing a CVD event among patients of different
ages but the same short-term cardiovascular risk. These
factors need to be considered when assessing the
potential impact of future CVD events in patients of
different ages.
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